Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of $ !
Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001, ISO 14001, GMP, HACCP
  • Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
  • Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
  • Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
  • Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
  • Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
  • Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
Find Similar Products
  • Overview
  • Product Description
  • Product Details
  • Application&Function
  • Specification
Overview

Basic Info.

Model NO.
D-sung Pioglitazone hydrochloride
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Adult
State
Powder
Purity
>99%
Product Name
Pioglitazone Hydrochloride
Name
Pioglitazone Hydrochloride Powder
Appearance
White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Pharmaceutical
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
112529-15-4
Mf
C19h21cln2o3s
MW
392.9
Melting Point
193-194 C
Density
1.26 g/cm3
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
1000kg/Month

Product Description

Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone hydrochloride
Product Description
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone HydrochlorideAntidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
Product Details
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
Product name Pioglitazone
Cas number 112529-15-4
Apperance White Powder
Density 1.26 g/cm3
MF C19H21ClN2O3S
Melting point 193-194ºC
MW 392.90000
Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of  dependent diabetes mellitus (NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester into thiazolidine. As with other representatives in this class, it potently activates the nuclear receptor peroxisome proliferator-activated receptor gamma which is believed to be involved in the regulation of  resistance and adipogenesis. In several obese and obese diabetic animal models, treatment with Pioglitazone resulted in reductions in plasma glucose and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs , was shown to significantly improve glycemic control in type-2 diabetes and demonstrated a beneficial effect on  resistance and other clinically relevant parameters as plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be safe and well tolerated and is said to have a lower occurrence of hepatic toxicity as well as a low probability for drug interaction.
Application&Function
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride

Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin.The main study that looked at the medication, however, found no statistically significant difference in the main cardiovascular outcomes that were looked at.
The secondary outcome of death from all causes, myocardial infarction, and stroke were lower. Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.

Specification
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone HydrochlorideAntidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone HydrochlorideAntidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone HydrochlorideAntidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone HydrochlorideAntidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
Antidiabetic CAS 112529-15-4 Pioglitazone Hydrochloride API Pioglitazone HCl Powder Pioglitazone Hydrochloride
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier